How to proceed in Helicobacter pylori-positive chronic gastritis refractory to first- and second-line eradication therapy.
نویسندگان
چکیده
Helicobacter pylori is a widespread disease causing most of the peptic ulcer diseases and low-grade mucosa-associated lymphoreticular tissue (MALT) lymphoma. Moreover, H. pylori is a proven environmental risk factor for gastric carcinoma and it has been recognized as a type 1 carcinogen factor. A combination of drugs has been proposed, using a proton pump inhibitor (PPI), amoxicillin, clarithromycin, metronidazole and tetracycline to treat the infection. Since 1996, according to the European guidelines, the first-line approach using PPI, amoxicillin and clarithromycin or metronidazole has been suggested. Seven days of quadruple therapy with PPI (or ranitidine), tetracycline, bismuth salts and metronidazole has been reserved as second-line treatment. To improve the eradication rate of the triple therapy, a different combination of the available antibiotics has been proposed, consisting of a 10-day sequential regimen. A second-line levofloxacin-amoxicillin-based triple therapy given for 10 days has been proposed, obtaining a high eradication rate, suggesting this regimen to be a suitable retreatment option in eradication failure. A third-line treatment with rifabutin-based regimen has been proposed.
منابع مشابه
Experiences with Helicobacter Pylori Treatment in Iran
Helicobacter pylori (H. Pylori) infection is currently recognized as the major cause of chronic active gastritis, peptic ulcer disease and mucosa associated lymphoid tissue (MALT) lymphoma and carcinoma of the stomach. Eradication of the infection will prevent the recurrence of the majority of such diseases. Different combined treatments have been tried in Iran for eradication of H. Pylori, but...
متن کاملComparing Clarithromycin- and Levofloxacin-Containing Triple Therapies for First Line Helicobacter pylori Eradication in Mazandran Province, Iran
Background and purpose: About half of the world’s population is infected with Helicobacter pylori (H. pylori). But, the efficacy of therapeutic regimens decreases over time due to increasing resistance of H. pylori to antibiotics. This research aimed at evaluating the efficacy of two triple therapy regimens. Materials and methods: This tudy was performed in Sari Imam Khomeini Hospital, 2016...
متن کاملEffects of Helicobacter Pylori Eradication on Chronic Idiopathic Urticaria
Background: Chronic idiopathic urticaria is defined as urticaria, which lasts for more than 8 weeks and has no apparent etiology. The aim of this study was to examine the causal role of Helicobacter pylori infection in chronic idiopathic urticaria. Methods: Fifty-six patients with chronic idiopathic urticaria and a negative response to skin prick test for common aeroallergens were selected. The...
متن کاملبررسی ارتباط تغییرات سطح سرمی گاسترین با ریشه کنی هلیکوباکترپیلوری
Background and purpose: H. pylori infection in the stomach is the first major cause of gastritis and peptic ulcer disease and gastric adenocarcinoma and lymphoma (MALT). Evaluation of the infection eradication is important. H. pylori infection is associated with gastric glands dysfunction such as increased serum gastrin and increased secretion of Pepsinogen. In recent years, the measurement ...
متن کاملInteraction between inflammatory mediators and miRNAs in Helicobacter pylori infection
Helicobacter pylori cause chronic inflammation favouring gastric carcinogenesis, and its eradication may prevent malignant transformation. We evaluated whether H. pylori infection and its eradication modify the expression of inflammatory mediators in patients with chronic gastritis. Furthermore, we assessed whether microRNAs modulate inflammatory pathways induced by H. pylori and identified miR...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Digestive diseases
دوره 25 3 شماره
صفحات -
تاریخ انتشار 2007